Neurocrine Biosciences, Inc.

NBIX·NasdaqGS·Healthcare
Compare
141.37−1.07 (−0.75%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
Pre-market141.00−0.37 (−0.26%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close142.44
Open142.37
Day range140.93143.63
52-week range122.14186.12
Off day high−1.57%
Off 52-week high−24.04%
Volume1.08M
Avg. volume (3M)1.29M
Market cap14.37B
EPS (TTM)6.87
Forward P/E11.82
P/E ratio (TTM)20.58
Dividend yield—
Beta (5Y)0.40
Shares outstanding101.65M
Short interest7.48% of float
Earnings dateNov 2, 2026
Analyst target207.29
Profit margin20.91%

Against its peers

Compare in full ›
NBIX ALKS SUPN AMLX BCRX AQST
Market cap 14.37B 6.75B 2.49B 3.45B 2.14B 603.71M
P/E (TTM) 20.6 105.9 — — — —
Forward P/E 11.8 22.3 9.6 -23.9 8.9 -8.4
Price/book 3.9 3.7 2.4 12.8 -4.7 -10.7
Dividend yield — — — — — —
1-year change +3.02% +26.05% −13.02% +93.66% +30.22% −30.09%
Today −0.75% −0.86% +0.33% −2.35% −2.22% +0.63%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

Latest news

All NBIX news ›
Defense World·Positive

Comparing Scilex (NASDAQ:SCLX) & Neurocrine Biosciences (NASDAQ:NBIX)

Posted by Defense World Staff on Oct 8th, 2026 Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Scilex (NASDAQ:SCLX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…

Stock Titan·

Neurocrine Biosciences CMO reports 51,331 shares

Neurocrine Biosciences (NBIX) is a neuroscience-focused biopharma company with FDA-approved treatments for tardive dyskinesia, Huntington’s chorea and adrenal disorders. - [Form 3] NEUROCRINE BIOSCIENCES INC Initial Statement of Beneficial…

From articles in the 4Search news index.

In the news

6mentions in 30 days
6with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.